Observational Cohort of HIV Infected Adults and Children in the PHPT Network Hospitals in Thailand - Full Text View

Purpose

Since 2004, the Thai Ministry of Public Health has massively scaled up antiretroviral treatment programs to provide therapy to more than 80,000 patients with partial support of the Global Fund to fight AIDS, Tuberculosis and Malaria (GFATM).

As access to HIV care continues to expand under the universal health coverage system, it is important to document and analyze the efficacy, tolerance, toxicity and acceptability of antiretroviral therapy within pilot treatment programs, to provide evidence based feedback and recommendations to the national program and policy makers.

Condition
HIV Infections


Study Type:	Observational
Study Design:	Observational Model: Cohort Time Perspective: Prospective
Official Title:	Observational Cohort of HIV Infected Adults and Children in the PHPT Network Hospitals in Thailand

Resource links provided by NLM:

MedlinePlus related topics: HIV/AIDS Health Facilities

U.S. FDA Resources

Further study details as provided by Gonzague Jourdain, Institut de Recherche pour le Developpement:

Biospecimen Retention: Samples With DNA

Blood samples


Estimated Enrollment:	2816
Study Start Date:	January 2007
Estimated Study Completion Date:	September 2020
Estimated Primary Completion Date:	September 2020 (Final data collection date for primary outcome measure)

Detailed Description:

As Thailand is rapidly expanding access to antiretroviral treatments under the universal health coverage system, it is crucial to document and learn from pilot antiretroviral treatment programs, in particular the medical outcomes and logistical, and organizational issues faced by hospital teams and patients in order to adapt the ARV delivery and monitoring system to various local settings.

Specific objectives

Analyze data collected in patients participating in the PHPT antiretroviral treatment program, in accordance to national and international guidelines, with no experimental interventions.
To determine factors associated with treatment outcome including immune status, virologic factors and antiretroviral drugs levels
To study the operational aspects of integrating comprehensive HIV care into the existing care system with regards to new activities generated at the hospital level (counseling, referral systems, biological monitoring), the impact on other health activities, mobilization of human and financial resources, affordability and sustainability.

The population of the study consists of approximately 2,000 consenting HIV-infected patients, including one-third of children, receiving HIV care as part of the GF-ATM or OXFAM Access to Antiretroviral programs, presenting at any of the PHPT network hospitals.

Eligibility


Ages Eligible for Study:	Child, Adult, Senior
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

HIV-infected Adults and Children

Criteria

Inclusion Criteria:

Adults and children (children are defined as less than 18 years old) patients are eligible for the inclusion in the cohort if they meet all the following inclusion criteria:
- Participation in the GFATM or Oxfam Access to Antiretroviral Programs
- For adults, consent to have their clinical or biological data used for this research study, and willingness to be followed at one of the PHPT network hospitals. For children, caregiver's consent to participate, willingness to bring the child to the scheduled visits for the duration of the treatment, and to have the child's clinical or biological data used for this research study.

Exclusion Criteria:

This is an observational study of an access to treatment program, therefore all patients who require treatment and are willing to be followed by the medical team and have their data collected can be enrolled in the study. The only exclusion criteria would be refusal to participate and the discontinuation criteria would be withdrawal of consent.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00433030

Locations


Thailand
Nopparat Rajathanee Hospital
Bungkum, Bangkok, Thailand
Bhumibol Adulyadej Hospital
Saimai, Bangkok, Thailand
Somdej Prapinklao Hospital
Samrae, Bangkok, Thailand
Chacheongsao Hospital
Muang, Chacheongsao, Thailand
Prapokklao Hospital
Muang, Chantaburi, Thailand
Doi Saket Hospital
Doi Saket, Chiang Mai, Thailand
Mae on Hospital
Mae on, Chiang Mai, Thailand
Nakornping Hospital
Mae Rim, Chiang Mai, Thailand
San Sai Hospital
San Sai, Chiang Mai, Thailand
Sankhampang Hospital
Sankhampang, Chiang Mai, Thailand
Sanpatong Hospital
Sanpatong, Chiang Mai, Thailand
Mae Chan Hospital
Mae Chan, Chiang Rai, Thailand
Mae Sai Hospital
Mae Sai, Chiang Rai, Thailand
Phan Hospital
Phan, Chiang Rai, Thailand
Chiangrai Prachanukroh Hospital
Muang, Chiangrai, Thailand
Chonburi Hospital
Muang, Chonburi, Thailand
Somdej Pranangchao Sirikit Hospital
Sattaheep, Chonburi, Thailand
Kalasin Hospital
Muang, Kalasin, Thailand
Phaholpolphayuhasena Hospital
Muang, Kanjanaburi, Thailand
Kranuan Crown Prince Hospital
Kranuan, Khon Kaen, Thailand
Khon Kaen Hospital
Muang, Khon Kaen, Thailand
Regional Health Promotion Centre 6, Khon Kaen
Muang, Khon Kaen, Thailand
Lampang Hospital
Muang, Lampang, Thailand
Lamphun Hospital
Muang, Lamphun, Thailand
Mahasarakam Hospital
Muang, Mahasarakam, Thailand
Nakhonpathom Hospital
Muang, Nakhonpathom, Thailand
Maharaj Nakornratchasrima Hospital
Muang, Nakornratchasrima, Thailand
Nong Khai Hospital
Muang, Nong Khai, Thailand
Pranangklao Hospital
Muang, Nonthaburi, Thailand
Chiang Kham Hospital
Chiang Kham, Phayao, Thailand
Phayao Provincial Hospital
Muang, Phayao, Thailand
Buddhachinaraj Hospital
Muang, Pitsanuloke, Thailand
Ratchaburi Hospital
Muang, Ratchaburi, Thailand
Rayong Hospital
Muang, Rayong, Thailand
Roi-et Hospital
Muang, Roi-et, Thailand
Samutprakarn Hospital
Pak Nam, Samutprakarn, Thailand
Samutsakorn Hospital
Muang, Samutsakorn, Thailand
Hat Yai Hospital
Hat Yai, Songkla, Thailand

Sponsors and Collaborators

Institut de Recherche pour le Developpement

Global Fund

Ministry of Health, Thailand

Investigators


Principal Investigator:	Gonzague JOURDAIN, MD, PhD	Institut de Recherche pour le Developpement

More Information

Additional Information:

PHPT Antiretroviral Treatment Cohorts This link exits the ClinicalTrials.gov site

Publications:

Collins IJ, Jourdain G, Hansudewechakul R, Kanjanavanit S, Hongsiriwon S, Ngampiyasakul C, Sriminiphant S, Technakunakorn P, Ngo-Giang-Huong N, Duong T, Le Coeur S, Jaffar S, Lallemant M; Program for HIV Prevention and Treatment Study Team. Long-term survival of HIV-infected children receiving antiretroviral therapy in Thailand: a 5-year observational cohort study. Clin Infect Dis. 2010 Dec 15;51(12):1449-57. doi: 10.1086/657401. Epub 2010 Nov 5.

Ngo-Giang-Huong N, Jourdain G, Amzal B, Sang-a-gad P, Lertkoonalak R, Eiamsirikit N, Tansuphasawasdikul S, Buranawanitchakorn Y, Yutthakasemsunt N, Mekviwattanawong S, McIntosh K, Lallemant M; Program for HIV Prevention and Treatment (PHPT) study group. Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: a bayesian analysis. PLoS One. 2011;6(11):e27427. doi: 10.1371/journal.pone.0027427. Epub 2011 Nov 23.

Jourdain G, Wagner TA, Ngo-Giang-Huong N, Sirirungsi W, Klinbuayaem V, Fregonese F, Nantasen I, Techapornroong M, Halue G, Nilmanat A, Wittayapraparat P, Chalermpolprapa V, Pathipvanich P, Yuthavisuthi P, Frenkel LM, Lallemant M; Program for HIV Prevention and Treatment (PHPT) Study Group. Association between detection of HIV-1 DNA resistance mutations by a sensitive assay at initiation of antiretroviral therapy and virologic failure. Clin Infect Dis. 2010 May 15;50(10):1397-404. doi: 10.1086/652148.

Wagner TA, Kress CM, Beck I, Techapornroong M, Wittayapraparat P, Tansuphasawasdikul S, Jourdain G, Ngo-Giang-Huong N, Lallemant M, Frenkel LM. Detection of HIV-1 drug resistance in women following administration of a single dose of nevirapine: comparison of plasma RNA to cellular DNA by consensus sequencing and by oligonucleotide ligation assay. J Clin Microbiol. 2010 May;48(5):1555-61. doi: 10.1128/JCM.02062-09. Epub 2010 Feb 24.

Fregonese F, Collins IJ, Jourdain G, Lecoeur S, Cressey TR, Ngo-Giang-Houng N, Banchongkit S, Chutanunta A, Techapornroong M, Lallemant M; Program for HIV Prevention and Treatment Study Group. Predictors of 5-year mortality in HIV-infected adults starting highly active antiretroviral therapy in Thailand. J Acquir Immune Defic Syndr. 2012 May 1;60(1):91-8. doi: 10.1097/QAI.0b013e31824bd33f.

Duong T, Jourdain G, Ngo-Giang-Huong N, Le Cœur S, Kantipong P, Buranabanjasatean S, Leenasirimakul P, Ariyadej S, Tansuphasawasdikul S, Thongpaen S, Lallemant M; Program for HIV Prevention and Treatment Study Group. Laboratory and clinical predictors of disease progression following initiation of combination therapy in HIV-infected adults in Thailand. PLoS One. 2012;7(8):e43375. Epub 2012 Aug 15.

Khamduang W, Gaudy-Graffin C, Ngo-Giang-Huong N, Jourdain G, Moreau A, Luekamlung N, Halue G, Buranawanitchakorn Y, Kunkongkapan S, Buranabanjasatean S, Lallemant M, Sirirungsi W, Goudeau A; Program for HIV Prevention and Treatment Study Group. Long-term hepatitis B virus (HBV) response to lamivudine-containing highly active antiretroviral therapy in HIV-HBV co-infected patients in Thailand. PLoS One. 2012;7(7):e42184. Epub 2012 Jul 31.

Collins IJ, Cairns J, Jourdain G, Fregonese F, Nantarukchaikul M, Lertpienthum N, Wannarit P, Attavinijtrakarn P, Layangool P, Le Coeur S, Lallemant M; Program for HIV Prevention and Treatment (PHPT) study team. Hospitalization trends, costs, and risk factors in HIV-infected children on antiretroviral therapy. AIDS. 2012 Sep 24;26(15):1943-52.

Puthanakit T, Jourdain G, Hongsiriwon S, Suntarattiwong P, Chokephaibulkit K, Sirisanthana V, Kosalaraksa P, Petdachai W, Hansudewechakul R, Siangphoe U, Suwanlerk T, Ananworanich J; HIV-NAT 086Study Team. HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. HIV Med. 2010 Oct 1;11(9):565-72. doi: 10.1111/j.1468-1293.2010.00828.x. Epub 2010 Mar 25.

Sukasem C, Cressey TR, Prapaithong P, Tawon Y, Pasomsub E, Srichunrusami C, Jantararoungtong T, Lallement M, Chantratita W. Pharmacogenetic markers of CYP2B6 associated with efavirenz plasma concentrations in HIV-1 infected Thai adults. Br J Clin Pharmacol. 2012 Dec;74(6):1005-12. doi: 10.1111/j.1365-2125.2012.04288.x.

Puthanakit T, Jourdain G, Suntarattiwong P, Chokephaibulkit K, Siangphoe U, Suwanlerk T, Prasitsuebsai W, Sirisanthana V, Kosalaraksa P, Petdachai W, Hansudewechakul R, Waranawat N, Ananworanich J; HIV-NAT 086 study team. High virologic response rate after second-line boosted protease inhibitor-based antiretroviral therapy regimens in children from a resource limited setting. AIDS Res Ther. 2012 Jun 18;9(1):20. doi: 10.1186/1742-6405-9-20.

Collins I, Cairns J, Le Coeur S, Pagdi K, Ngampiyaskul C, Layangool P, Borkird T, Na-Rajsima S, Wanchaitanawong V, Jourdain G, Lallemant M. Five-year trends in antiretroviral usage and drug costs in HIV-infected children in Thailand. J Acquir Immune Defic Syndr. 2013 Sep 1;64(1):95-102. doi: 10.1097/QAI.0b013e318298a309.

Tang MW, Rhee SY, Bertagnolio S, Ford N, Holmes S, Sigaloff KC, Hamers RL, de Wit TF, Fleury HJ, Kanki PJ, Ruxrungtham K, Hawkins CA, Wallis CL, Stevens W, van Zyl GU, Manosuthi W, Hosseinipour MC, Ngo-Giang-Huong N, Belec L, Peeters M, Aghokeng A, Bunupuradah T, Burda S, Cane P, Cappelli G, Charpentier C, Dagnra AY, Deshpande AK, El-Katib Z, Eshleman SH, Fokam J, Gody JC, Katzenstein D, Koyalta DD, Kumwenda JJ, Lallemant M, Lynen L, Marconi VC, Margot NA, Moussa S, Ndung'u T, Nyambi PN, Orrell C, Schapiro JM, Schuurman R, Sirivichayakul S, Smith D, Zolfo M, Jordan MR, Shafer RW. Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine. J Infect Dis. 2013 Jun 15;207 Suppl 2:S70-7. doi: 10.1093/infdis/jit114.

Collins IJ, Cairns J, Ngo-Giang-Huong N, Sirirungsi W, Leechanachai P, Le Coeur S, Samleerat T, Kamonpakorn N, Mekmullica J, Jourdain G, Lallemant M; Programme for HIV Prevention and Treatment Study Team. Cost-effectiveness of early infant HIV diagnosis of HIV-exposed infants and immediate antiretroviral therapy in HIV-infected children under 24 months in Thailand. PLoS One. 2014 Mar 14;9(3):e91004. doi: 10.1371/journal.pone.0091004. eCollection 2014.

Suaysod R, Ngo-Giang-Huong N, Salvadori N, Cressey TR, Kanjanavanit S, Techakunakorn P, Krikajornkitti S, Srirojana S, Laomanit L, Chalermpantmetagul S, Lallemant M, Le Cœur S, McIntosh K, Traisathit P, Jourdain G. Treatment Failure in HIV-Infected Children on Second-line Protease Inhibitor-Based Antiretroviral Therapy. Clin Infect Dis. 2015 Jul 1;61(1):95-101. doi: 10.1093/cid/civ271. Epub 2015 Apr 1.

Riyaten P, Salvadori N, Traisathit P, Ngo-Giang-Huong N, Cressey TR, Leenasirimakul P, Techapornroong M, Bowonwatanuwong C, Kantipong P, Nilmanat A, Yutthakasemsunt N, Chutanunta A, Thongpaen S, Klinbuayaem V, Decker L, Le Cœur S, Lallemant M, Capeau J, Mary JY, Jourdain G. New-Onset Diabetes and Antiretroviral Treatments in HIV-Infected Adults in Thailand. J Acquir Immune Defic Syndr. 2015 Aug 1;69(4):453-9. doi: 10.1097/QAI.0000000000000647.


Responsible Party:	Gonzague Jourdain, Senior Researcher, Institut de Recherche pour le Developpement
ClinicalTrials.gov Identifier:	NCT00433030 History of Changes
Other Study ID Numbers:	PHPT-Cohort
Study First Received:	February 8, 2007
Last Updated:	August 16, 2017

Keywords provided by Gonzague Jourdain, Institut de Recherche pour le Developpement:


Highly Active Antiretroviral Therapy HIV Viral load HIV drug Resistance Thailand

Additional relevant MeSH terms:


HIV Infections Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases	Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases

ClinicalTrials.gov processed this record on September 21, 2017